Prediction of remission of type 2 diabetes mellitus after bariatric surgery
https://doi.org/10.14341/DM12814
Abstract
Type 2 diabetes prevalence is increasing dramatically worldwide. Conservative therapy doesn’t bring stable effect and is often insufficient, not to mention the lack of prospects to cure the disease. Fortunately, accumulating evidence points towards the notion that a complete remission of type 2 diabetes is feasible following a choice of surgical interventions. The efficacy of bariatric surgery in particular for achieving glycemic control has highlighted surgery as a candidate curative intervention for type 2 diabetes. When compared to intensive medical therapy and lifestyle intervention, metabolic surgery has shown superiority in achieving reducing number of medications and metabolic factors improvement, which translates in long-term benefits on diabetes progression and complications. Understanding factors that predict diabetes remission can help to select patients who will benefit most from bariatric surgery and to choose the most effective type of operation. This literature review analyzes studies of the most significant clinical and biochemical predictors of remission of type 2 diabetes mellitus after bariatric interventions, as well as highlights well-known mathematical prediction models.
About the Authors
O. V. Kornyushin
V.A. Almazov National Medical Research Center
Competing Interests:
Oleg V. Kornyushin, MD, PhD
SPIN: 4525-2712
St. Petersburg
Competing Interests:
no
I. S. Sakeian
V.A. Almazov National Medical Research Center
Competing Interests:
Inga S. Sakeian
Researcher ID: AAX-9221-2021
St. Petersburg
Competing Interests:
no
E. N. Kravchuk
V.A. Almazov National Medical Research Center
Competing Interests:
Ekaterina N. Kravchuk, MD, PhD
Researcher ID: AAB-5672-2020
SPIN: 3245-0237
St. Petersburg
Competing Interests:
no
D. I. Vasilevsky
V.A. Almazov National Medical Research Center
Competing Interests:
Dmitri I. Vasilevsky, MD, PhD, associate professor
SPIN: 7598-6339
St. Petersburg
Competing Interests:
no
I. N. Danilov
V.A. Almazov National Medical Research Center
Competing Interests:
Ivan N. Danilov, MD, PhD
SPIN: 3267-5056
St. Petersburg
Competing Interests:
no
A. E. Neimark
V.A. Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
Aleksandr E. Neimark, MD, PhD
SPIN: 6554-3217
Scopus Author ID: 8454779100
2 Akkuratov street, 197341 St. Petersburg
Competing Interests:
no
References
1. Shestakova MV, Sklyanik IA, Dedov II. Is it possible to achieve sustained remission or cure of type 2 diabetes mellitus in the 21st century? Ter Arkh. 2017;89(10):4-11. (In Russ.). doi: https://doi.org/10.17116/terarkh201789104-11
2. Sklyanik IA, Shestakova EA, Yurasov AV, at al. Glycemia normalization in patients with obesity and type 2 diabetes mellitus: bariatric surgery vs pharmacological therapy. Ter Arkh. 2019;91(10):34-38. (In Russ.). doi: https://doi.org/10.26442/00403660.2019.10.000375
3. Aminian A, Zajichek A, Arterburn DE, et al. Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity. JAMA. 2019;322(13):1271-1282. doi: https://doi.org/10.1001/jama.2019.14231
4. Rubino F, Nathan DM, Eckel RH, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care. 2016;39(6):861-877. doi: https://doi.org/10.2337/dc16-0236
5. Pories WJ, Card JF, Flickinger EG, et al. The Control of Diabetes Mellitus (NIDDM) in the Morbidly Obese with the Greenville Gastric Bypass. Ann Surg. 1987;206(3):316-323. doi: https://doi.org/10.1097/00000658-198709000-00009
6. Yashkov YI. Vozmozhnosti korrektsii narusheniy uglevodnogo obmena pri sakharnom diabete 2 tipa s primeneniem bariatricheskikh operatsiy. Diabetes mellitus. 2000;3(2):26-29. (In Russ.). doi: https://doi.org/10.14341/2072-0351-5883
7. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724-1737. doi: https://doi.org/10.1001/jama.292.14.1724
8. Sjöholm K, Pajunen P, Jacobson P, et al. Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study. Diabetologia. 2015;58(7):1448-1453. doi: https://doi.org/10.1007/s00125-015-3591-y
9. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes. N Engl J Med. 2014;370(21):2002-2013. doi: https://doi.org/10.1056/NEJMoa1401329
10. Ikramuddin S, Korner J, Lee W-J, et al. Roux-en-Y Gastric Bypass vs Intensive Medical Management for the Control of Type 2 Diabetes, Hypertension, and Hyperlipidemia. JAMA. 2013;309(21):2240-2249. doi: https://doi.org/10.1001/jama.2013.5835
11. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial — a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219-234. doi: https://doi.org/10.1111/joim.12012
12. Kim S, Richards WO. Long-Term Follow-up of the Metabolic Profiles in Obese Patients With Type 2 Diabetes Mellitus After Roux-en-Y Gastric Bypass. Ann Surg. 2010;251(6):1049-1055. doi: https://doi.org/10.1097/SLA.0b013e3181d9769b
13. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of Laparoscopic Roux-En Y Gastric Bypass on Type 2 Diabetes Mellitus. Ann Surg. 2003;238(4):467-485. doi: https://doi.org/10.1097/01.sla.0000089851.41115.1b
14. de Hollanda A, Lecube A, Rubio MA, et al. New Metrics to Assess Type 2 Diabetes after Bariatric Surgery: The “Time-Within-Remission Range.” J Clin Med. 2020;9(4):1070. doi: https://doi.org/10.3390/jcm9041070
15. Dang JT, Sheppard C, Kim D, et al. Predictive factors for diabetes remission after bariatric surgery. Can J Surg. 2019;6(5):315-319. doi: https://doi.org/10.1503/cjs.014516
16. Ershova EV, Yashkov YI. Status of carbohydrate and lipid metabolism in obese patients with type 2 diabetes mellitus after biliopancreatic diversion surgery. Obe Metab. 2013;10(3):28-36. (In Russ.). doi: https://doi.org/10.14341/2071-8713-3862
17. Camerini GB, Papadia FS, Carlini F, et al. The long-term impact of biliopancreatic diversion on glycemic control in the severely obese with type 2 diabetes mellitus in relation to preoperative duration of diabetes. Surg Obes Relat Dis. 2016;12(2):345-349. doi: https://doi.org/10.1016/j.soard.2015.05.012
18. Chikunguwo SM, Wolfe LG, Dodson P, et al. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2010;6(3):254-259. doi: https://doi.org/10.1016/j.soard.2009.11.003
19. Purnell JQ, Dewey EN, Laferrère B, et al. Diabetes Remission Status During Seven-year Follow-up of the Longitudinal Assessment of Bariatric Surgery Study. J Clin Endocrinol Metab. 2021;106(3):774-788. doi: https://doi.org/10.1210/clinem/dgaa849
20. DiGiorgi M, Rosen DJ, Choi JJ, et al. Re-emergence of diabetes after gastric bypass in patients with mid- to longterm follow-up. Surg Obes Relat Dis. 2010;6(3):249-253. doi: https://doi.org/10.1016/j.soard.2009.09.019
21. Ikramuddin S, Billington CJ, Lee W-J, et al. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. Lancet Diabetes Endocrinol. 2015;3(6):413- 422. doi: https://doi.org/10.1016/S2213-8587(15)00089-3
22. Yan W, Bai R, Yan M, Song M. Preoperative Fasting Plasma C-Peptide Levels as Predictors of Remission of Type 2 Diabetes Mellitus after Bariatric Surgery: A Systematic Review and Meta-Analysis. J Investig Surg. 2017;30(6):383-393. doi: https://doi.org/10.1080/08941939.2016.1259375
23. Sklyanik IA. Remissija saharnogo diabeta 2 tipa pri ispol’zovanii medikamentoznogo (liraglutid) i bariatricheskih metodov lechenija: sroki nastuplenija, prognosticheskie faktory, mehanizmy. [dissertation] Moscow; 2020. (In Russ.) Доступно по: https://www.endocrincentr.ru/sites/default/files/specialists/science/dissertation/sklyanik_ia_dissertacia.pdf. Ссылка активна на 10.12.2021.
24. Kaur R, Kim D, Cutfield R, et al. Good Glycemic Outcomes Following Bariatric Surgery Among Patients With Type 2 Diabetes, Obesity, and Low-Titer GAD Antibodies. Diabetes Care. 2021;44(2):607-609. doi: https://doi.org/10.2337/dc20-0804
25. Ceperuelo-Mallafré V, Llauradó G, Keiran N, et al. Preoperative Circulating Succinate Levels as a Biomarker for Diabetes Remission After Bariatric Surgery. Diabetes Care. 2019;42(10):1956-1965. doi: https://doi.org/10.2337/dc19-0114
26. Izaguirre M, Gómez-Ambrosi J, Rodríguez A, et al. GLP-1 Limits Adipocyte Inflammation and Its Low Circulating Pre-Operative Concentrations Predict Worse Type 2 Diabetes Remission after Bariatric Surgery in Obese Patients. J Clin Med. 2019;8(4):479. doi: https://doi.org/10.3390/jcm8040479
27. Guo X, Zhang S, Zhang Q, et al. Neutrophil:lymphocyte ratio is positively related to type 2 diabetes in a large-scale adult population: a Tianjin Chronic Low-Grade Systemic Inflammation and Health cohort study. Eur J Endocrinol. 2015;173(2):217-225. doi: https://doi.org/10.1530/EJE-15-0176
28. Bonaventura A, Liberale L, Carbone F, et al. Baseline neutrophilto-lymphocyte ratio is associated with long-term T2D remission after metabolic surgery. Acta Diabetol. 2019;56(7):741-748. doi: https://doi.org/10.1007/s00592-019-01345-2
29. Hayes MT, Hunt LA, Foo J, et al. A Model for Predicting the Resolution of Type 2 Diabetes in Severely Obese Subjects Following Roux-en Y Gastric Bypass Surgery. Obes Surg. 2011;21(7):910-916. doi: https://doi.org/10.1007/s11695-011-0370-9
30. Ramos-Levi AM, Matia P, Cabrerizo L, et al. Statistical models to predict type 2 diabetes remission after bariatric surgery. J Diabetes. 2014;6(5):472-477. doi: https://doi.org/10.1111/1753-0407.12127
31. Lee WJ, Hur KY, Lakadawala M, et al. Predicting success of metabolic surgery: Age, body mass index, C-peptide, and duration score. Surg Obes Relat Dis. 2013;9:379-384. doi: https://doi.org/10.1016/j.soard.2012.07.015
32. Still CD, Wood GC, Benotti P, et al. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabetes Endocrinol. 2014;2(1):38-45. doi: https://doi.org/10.1016/S2213-8587(13)70070-6
33. Still CD, Benotti P, Mirshahi T, et al. DiaRem2: Incorporating duration of diabetes to improve prediction of diabetes remission after metabolic surgery. Surg Obes Relat Dis. 2019;15(5):717-724. doi: https://doi.org/10.1016/j.soard.2018.12.020
34. Aminian A, Brethauer SA, Andalib A, et al. Individualized Metabolic Surgery Score. Ann Surg. 2017;266(4):650-657. doi: https://doi.org/10.1097/SLA.0000000000002407
Supplementary files
Review
For citations:
Kornyushin O.V., Sakeian I.S., Kravchuk E.N., Vasilevsky D.I., Danilov I.N., Neimark A.E. Prediction of remission of type 2 diabetes mellitus after bariatric surgery. Diabetes mellitus. 2021;24(6):565-570. (In Russ.) https://doi.org/10.14341/DM12814
Views:
2118
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
